Apple v. Omni MedSci: Federal Circuit Affirms-in-Part, Vacates-in-Part on Biosensor Patent
Apple challenged Omni MedSci’s US10517484B2 — covering a semiconductor diode-based physiological measurement device with improved signal-to-noise ratio — at the Federal Circuit. After 618 days, the court issued a split decision: affirming some rulings below while vacating others and remanding, leaving key issues unresolved.
Federal Circuit splits the difference in Apple–Omni MedSci biosensor dispute
Apple, Inc. appealed to the United States Court of Appeals for the Federal Circuit (Case No. 23-1034) against Omni MedSci, Inc., a medtech IP holding company asserting US10517484B2. That patent covers a semiconductor diode-based physiological measurement device engineered for improved signal-to-noise ratio — technology directly relevant to wearable health monitoring systems such as those embedded in consumer smartwatches. The appeal was docketed on 12 October 2022 before a panel comprising Judges Reyna, Cunningham, and Albright.
The Federal Circuit closed the matter on 21 June 2024 with a nuanced disposition: affirmed-in-part, vacated-in-part, and remanded. This split outcome means the lower court’s rulings survived appellate scrutiny on some claims or issues, while the panel found reversible error on at least one discrete matter, nullifying that portion and returning it to the originating tribunal for further proceedings consistent with the appellate opinion. Neither party achieved a clean win.
At 618 days, the appeal duration suggests the panel grappled with substantive technical or claim-construction questions rather than disposing of the case on purely procedural grounds. The remand leaves commercial uncertainty intact: Omni MedSci’s patent survives in part, meaning Apple — and potentially other wearable device manufacturers — faces continued exposure on the unresolved remanded issues. The precise scope of what was affirmed versus vacated is determinative for any freedom-to-operate analysis in the biosensor space.
Filing to Case Remanded in 618 days
618 days — longer than the median Federal Circuit appeal, suggesting substantive briefing complexity
Federal Circuit affirms-in-part, vacates-in-part: what the split ruling means
What ‘affirmed-in-part, vacated-in-part, remanded’ means
A split Federal Circuit disposition indicates the panel found no reversible error on certain issues below — those portions stand — while identifying at least one legal or factual error warranting vacatur. Vacating part of a lower decision nullifies it; remand instructs the originating court to reconsider that portion under the appellate guidance. This is not a final resolution: the case continues below on remanded issues.
Partial affirmance + remandOmni MedSci: patent survives in part, but remand reopens risk
The affirmed portions of the ruling below remain intact, meaning Omni MedSci’s US10517484B2 retains enforceability on those claims or issues confirmed by the Federal Circuit. However, the vacated-in-part disposition resets at least one material issue, which may affect damages, claim scope, or liability findings on remand. Omni MedSci cannot yet claim a final victory against Apple on all fronts.
Partial patent survivalApple: partial win on appeal, but case continues below
Apple succeeded in persuading the Federal Circuit that at least one aspect of the lower decision was legally flawed — a meaningful result at the appellate level. The vacated portion returns to the lower tribunal, giving Apple another opportunity to contest the relevant issues. Nevertheless, the affirmed portions limit Apple’s total relief: it could not unwind all findings made against it, and infringement exposure on surviving claims persists pending the remand outcome.
Partial appellate reliefContinued IP risk for wearable biosensor manufacturers
The partial affirmance signals that US10517484B2 covers technology the Federal Circuit considers at least partly viable — a strong signal for competitors in the wearable health monitoring space. Companies designing semiconductor diode-based physiological sensors with SNR-optimisation features should treat this patent as an active enforcement risk. The remand also means the litigation landscape remains fluid, making real-time monitoring of this docket commercially important for product teams.
Ongoing FTO riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Apple, Inc. | Company | Consumer electronics — appellant challenging Omni MedSci’s US10517484B2 biosensor patentSearch in Eureka ↗ |
| Defendant | Omni MedSci, Inc. | Company | Medtech IP holding company — asserting wearable physiological sensing patent portfolioSearch in Eureka ↗ |
| Plaintiff counsel | Jeffrey Paul Kushan Esq. | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Joshua John Fougere | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael Roberts | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Thomas Anthony Broughan, III | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sidley Austin LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Christopher C. Smith | Attorney | Counsel for Omni MedSci, Inc.Search in Eureka ↗ |
| Defendant counsel | John S. LeRoy | Attorney | Counsel for Omni MedSci, Inc.Search in Eureka ↗ |
| Defendant counsel | Thomas A. Lewry Esq. | Attorney | Counsel for Omni MedSci, Inc.Search in Eureka ↗ |
| Defendant law firm | Brooks Kushman PC | Law Firm | Representing Omni MedSci, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Reyna | CUNNINGHAM | ALBRIGHT | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s ‘affirmed-in-part, vacated-in-part and remanded’ disposition reflects a nuanced appellate review applying de novo scrutiny to legal questions — most likely claim construction — while deferring on factual findings absent clear error. The partial vacatur indicates the panel identified at least one reversible legal error below. The remand is not a final defeat for either side: affirmed portions bind the lower court, while vacated issues are reconsidered fresh. Both parties retain live interests in the remand proceedings.
US10517484B2 — Semiconductor Diode-Based Physiological Measurement Device
US10517484B2 (application no. US16/506885) protects a physiological measurement device architecture built on semiconductor diodes, specifically engineered to achieve an improved signal-to-noise ratio in biological signal acquisition. This technical profile is directly applicable to wearable health monitors — devices that use optical or electronic sensing to measure continuous biometric data such as blood oxygen saturation, heart rate, or glucose proxies through the skin. The patent’s SNR-focus addresses one of the core engineering challenges in miniaturised wearable sensors: separating weak biological signals from ambient and motion-induced noise.
For the wearable technology sector, this patent sits at the intersection of consumer electronics and medical-grade sensing — a commercially high-value space driven by Apple Watch, Fitbit, and emerging continuous health monitoring platforms. Omni MedSci’s willingness to litigate through Federal Circuit appeal against Apple — one of the world’s largest consumer electronics companies — signals strong conviction in the patent’s scope and value. Competitors designing photoplethysmography modules, pulse oximetry circuits, or any semiconductor diode array used in biometric wearables face meaningful freedom-to-operate questions until the remand proceedings yield a final claim construction.
Should your team run an FTO analysis against US10517484B2?
If your organisation designs, manufactures, or integrates semiconductor diode-based sensing modules into wearable health devices — including smartwatches, fitness trackers, continuous glucose monitors, or clinical wearables — US10517484B2 warrants priority attention. The Federal Circuit’s partial affirmance means the patent has survived the most rigorous appellate scrutiny the US system applies. Product teams shipping SNR-optimised optical biosensors, PPG front-ends, or diode-array health sensors should not assume the Apple litigation resolves their own exposure.
PatSnap Eureka’s FTO Search Agent can map your specific product architecture against the claim trees of US10517484B2, flag prosecution history estoppel created during the application lifecycle of US16/506885, and surface prior art that may support an IPR petition. With the remand still active, claim scope could shift — Eureka’s real-time docket monitoring keeps your FTO analysis current as the case evolves below.
Run a freedom-to-operate analysis on US10517484B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit biosensor and wearable health patent appeals
Explore Federal Circuit appeals involving wearable health monitoring, physiological sensing, and semiconductor-based biometric device patents similar to US10517484B2.
What this case signals for the wearable biosensor IP landscape
A split Federal Circuit outcome on a core wearable health-sensing patent leaves the competitive field uncertain — and raises the stakes for any product team in this space.
US10517484B2 is a live enforcement risk — partial affirmance confirms it
The Federal Circuit’s decision to affirm at least part of the lower ruling validates the patent’s enforceability on certain issues. Any company commercialising semiconductor diode-based physiological measurement devices — particularly those optimising signal-to-noise ratio for wearable use — should treat this patent as a priority FTO target, not a resolved matter.
Remand means the litigation is not over — monitor the docket
The vacated-in-part disposition sends live issues back to the lower court. For in-house counsel and product teams at competing wearable device makers, the remand outcome could reset damages exposure, claim scope, or liability findings. Passive monitoring is insufficient; active docket tracking is warranted until a final, unappealable resolution is reached.
Apple v Omni — key questions answered
The Federal Circuit issued an affirmed-in-part, vacated-in-part and remanded decision on 21 June 2024. The panel upheld some aspects of the lower court’s rulings on US10517484B2 while finding reversible error on at least one issue, nullifying that portion and returning it for further proceedings. Neither party achieved a complete victory.
US10517484B2 (application US16/506885) covers a semiconductor diode-based physiological measurement device engineered for improved signal-to-noise ratio. This technology is relevant to Apple because it aligns with the biosensor architecture used in wearable health monitors such as the Apple Watch, which measures biometric data including heart rate and blood oxygen levels using optical sensing.
Remand means the vacated portion of the lower court’s decision is sent back to that court for reconsideration consistent with the Federal Circuit’s opinion. The case is not fully resolved. Issues such as claim scope, damages, or liability findings on the remanded matters remain live and will be re-adjudicated below, meaning both parties face continued litigation risk and cost.
The public record of this appeal does not allow a definitive conclusion that Apple was found to infringe. The affirmed-in-part disposition confirms the lower court was correct on certain issues, but the specific issues affirmed versus vacated are not fully detailed in the high-level case data. The remand suggests at least one material issue — potentially including infringement or claim scope — remains unresolved.
Apple was represented by Sidley Austin LLP, with lead counsel including Jeffrey Paul Kushan, Joshua John Fougere, Michael Roberts, and Thomas Anthony Broughan III. Omni MedSci was represented by Brooks Kushman PC, with counsel including Christopher C. Smith, John S. LeRoy, and Thomas A. Lewry.
PatSnap Eureka searches patents and litigation data to answer instantly.